VALIDATING THE RESULTS OF A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) IN MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Hatswell, A. [1 ]
Batteson, R. [1 ]
Hook, E. [1 ]
Wheat, H. [1 ]
Vioix, H. [2 ]
McLean, T. [3 ]
Alexopoulos, S. [3 ]
Baijal, S. [4 ]
机构：
[1] Delta Hat Ltd, Nottingham, England
[2] Merck Healthcare KGaA, Darmstadt, Germany
[3] Merck Serono Ltd, Feltham, England
[4] Univ Hosp Birmingham NHS Trust, Birmingham, W Midlands, England
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO23
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [1] MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF TEPOTINIB WITH CAPMATINIB IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) WITH MET EXON 14 (METEX14) SKIPPING
    Paik, P.
    Pfeiffer, B.
    Vioix, H.
    Postma, M. J.
    VALUE IN HEALTH, 2022, 25 (12) : S28 - S28
  • [2] Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC)
    Marks, Jennifer Aline
    Gandhi, Nishant
    Halmos, Balazs
    Ramalingam, Suresh S.
    Bazhenova, Lyudmila
    Marmarelis, Melina Elpi
    Xiu, Joanne
    Walker, Phillip
    Oberley, Matthew James
    Ma, Patrick C.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
    Spira, A.
    Krebs, M.
    Cho, B. C.
    Besse, B.
    Goldman, J.
    Janne, P.
    Lee, C. K.
    Ma, Z.
    Mansfield, A.
    Minchom, A.
    Ou, S.
    Salgia, R.
    Wang, Z.
    Gao, G.
    Curtin, J.
    Roshak, A.
    Schnepp, R.
    Thayu, M.
    Knoblauch, R.
    Trigo, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S874 - S875
  • [4] TEPOTINIB COMPARED WITH CHEMOIMMUNOTHERAPY IN FIRST-LINE NON-SMALL CELL LUNG CANCER (NSCLC): MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) OF VISION IN MET EXON 14 (METEX14) SKIPPING NSCLC AND KEYNOTE-189 IN WILD-TYPE NSCLC
    Vioix, H.
    Hatswell, A.
    McLean, T.
    Day, C.
    Batteson, R.
    Hook, E.
    Alexopoulos, S.
    Baijal, S.
    VALUE IN HEALTH, 2022, 25 (12) : S36 - S36
  • [5] TEPOTINIB VERSUS CHEMOTHERAPY IN MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC): REAL-WORLD EVIDENCE (RWE) AND MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) TO EXPLORE THE IMPACT OF SUBSEQUENT THERAPY
    Wheat, H.
    Hatswell, A.
    Christopoulos, P.
    Ekman, S.
    Guisier, F.
    Hook, E.
    Vioix, H.
    VALUE IN HEALTH, 2023, 26 (12) : S545 - S545
  • [6] Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
    Reinmuth, N.
    Popat, S.
    Paz-Ares, L.
    Knowles, E.
    Hatswell, A.
    McLean, T.
    Adrian, S.
    Gaumond, B.
    Vioix, H.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S985 - S986
  • [7] Tepotinib and Capmatinib in Patients with MET exon 14 Skipping NSCLC: A Matching Adjusted Indirect Comparison (MAIC)
    Pfeiffer, B. M.
    Postma, M. J.
    Hatswell, A.
    Vioix, H.
    Paik, P. K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S664 - S665
  • [8] Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
    Scherz, A.
    Felip, E.
    Garassino, M.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E.
    Mazieres, J.
    Cortot, A.
    Raskin, J.
    Viteri, S.
    Iams, W. Thomas
    Kim, H. R.
    Yang, J. -J.
    Stroh, C.
    Otto, G.
    Bruns, R.
    Paik, P.
    SWISS MEDICAL WEEKLY, 2021, 151 : 36 - 36
  • [9] Characterization of MET exon 14 skipping alterations (METex14) in non-small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS).
    Kim, So Yeon
    Bohlman, Stephen
    Yin, Jun
    Cheng, Haiying
    Walker, Phillip
    Dacic, Sanja
    Kim, Chul
    Khan, Hina
    Liu, Stephen V.
    Ma, Patrick C.
    Nagasaka, Misako
    Reckamp, Karen L.
    Abraham, Jim
    Uprety, Dipesh
    Halmos, Balazs
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] MOMENT REGISTRY (MET NON SMALL CELL CANCER REGISTRY) FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    Thomas, M.
    Christopoulos, P.
    Iams, W. T.
    Mazieres, J.
    Cortot, A. B.
    Peled, N.
    Minuti, G.
    Smit, E. F.
    Ahrens, S.
    Berghoff, K.
    Eggleton, S. P.
    Fries, F.
    Liu, P.
    Mahmoudpour, S. H.
    Menzel, C.
    O'Brate, A.
    Stroh, C.
    Oksen, D.
    VALUE IN HEALTH, 2023, 26 (12) : S527 - S527
12345